According to diabetes news reports, a class of diabetes drug could increase the risk of death by between 24% and 61%, as well as increasing heart failure by 30%. The report was published by the British Medical Journal, and concerned the diabetes drug group called sulphonylureas.
According to the report, the warning only applies to those people that take the drugs alone, not to those that combine with metformin . Sulphonylureas include some widely prescribed forms of diabetes drugs, including: glibenclamide, gliclazide, glimerpirizide, glipizide, and gliquidone.
Lead researcher Dr. Ioanna Tzoulaki of Imperial College London reportedly commented: "When we looked at metformin and sulphonylureas together we didn’t see an increased risk of heart failure or death. This might be because the sulphonylureas dose used when it is in combination with metformin is not as high as on its own, so you might not see the effect. It is also possible that metformin could be protective. Other studies looking at the drugs together have been inconclusive. It’s very important that people do not stop taking their medication as a result of this study."
Death risk increased 60 per cent by diabetes drug
Fri, 04 Dec 2009
Recommended links
Diabetes forumDiabetes based financial services
Diabetes myLifestyle
Diabetes donate
Diabetes pensions and annuities
Diabetes alert ID wristband
The Diet Plate to Help People with Diabetes
New type 1 diabetes drug
Diabetes drug warning has doctors on alert
Label change for type 2 diabetes drug
Diabetes prevention using diet, not drugs
Diabetes drug better for weight loss
Diabetes drug may have pancreatitis risk
Denial over diabetes drug link
Heart risk not alleviated by diabetes drugs
Obesity increases diabetes drug bill
Med diet could delay diabetes drugs
Diabetes drug prescriptions must stop, study says
Stop prescribing diabetes drug, scientists say
New diabetes drug same price
Dementia drug risk amongst people with diabetes
Iron binding drug could help diabetes neuropathy
Diabetes drug cleared of cancer risk
Canada reviews diabetes drug
Diabetes drug review causes share climb
Sanofi maintain diabetes drug no riskier than insulin
Diabetes drug cleared for European market
Drug association encourages use of diabetes drug
Diabetes drug requires more research, FDA rule
Takeda diabetes drug setback
Diabetes drug reaching stage three trials





Join us